Special Issue

Long COVID: Pathophysiology, Symptoms, Treatment, and Management

Message from the Guest Editors

The symptoms of persistent coronavirus disease 2019 are increasingly well reported in the literature. These persistent symptoms following acute infection, also known as 'long COVID', have affected people worldwide. Long COVID is a heterogeneous disease with multimorbidities affecting several physiological systems. Given the pandemic's spread, the number of individuals suffering from long COVID is significant, currently estimated at over 100 million. Therefore, regularly collating high-quality research and innovative recovery solutions across various research areas is crucial. Our aim in launching this Special Issue is to consider long COVID pathophysiology, symptomology, treatment strategies, and management strategies, aiming to guide the process from benchtop to bedside. Additionally, articles within this Special Issue will explore the socioeconomic impact of long COVID, the role of rehabilitation programs, and the effectiveness of emerging therapeutic approaches. A multidisciplinary perspective is essential in understanding the full scope of long COVID, as it affects not only physical health but also mental well-being, quality of life, and workforce participation.

Guest Editors

Dr. Lawrence D. Hayes

Lancaster University Medical School, Lancaster University, Lancaster, UK

Dr. Nilihan Sanal Hayes

School of Health and Society, University of Salford, Salford M5 4WT, UK

Deadline for manuscript submissions

31 January 2026



COVID

an Open Access Journal by MDPI

Impact Factor 1.0 CiteScore 2.3



mdpi.com/si/233256

COVID
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34

mdpi.com/journal/covid

covid@mdpi.com





an Open Access Journal by MDPI

Impact Factor 1.0
CiteScore 2.3



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *COVID*. *COVID* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. With the efforts of our professional team and the great potential of *COVID* topics, the impact factor of this journal will dramatically increase in the coming years. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Giuseppe Novelli

Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, 00133 Rome, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Immunology and Microbiology (miscellaneous))

